Literature DB >> 18978522

CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.

Séverine Crettol1, Jean-Pierre Venetz, Massimiliano Fontana, John-David Aubert, Manuel Pascual, Chin B Eap.   

Abstract

Cyclosporine is a substrate of cytochrome P450 (CYP) 3A and of the transporter ABCB1, for which polymorphisms have been described. In particular, CYP3A5 *3/*3 genotype results in the absence of CYP3A5 activity, whereas CYP3A7 *1/*1C genotype results in high CYP3A7 expression in adults. Log-transformed dose-adjusted cyclosporine trough concentration and daily dose per weight were compared 1, 3, 6, and 12 months after transplantation between CYP3A and ABCB1 genotypes in 73 renal (n = 64) or lung (n = 9) transplant recipients. CYP3A5 expressors (*1/*3 genotype; n = 8-10) presented significantly lower dose-adjusted cyclosporine trough concentrations (P < 0.05) and required significantly higher daily doses per weight (P < 0.01) than the nonexpressors (*3/*3 genotype; n = 55-59) 1, 3, 6, and 12 months after transplantation. In addition, 7 days after transplantation, more CYP3A5 expressors had uncorrected trough cyclosporine concentration below the target concentration of 200 ng/mL than the nonexpressors (odds ratio = 7.2; 95% confidence interval = 1.4-37.3; P = 0.009). CYP3A4 rs4646437C>T influenced cyclosporine kinetics, the T carriers requiring higher cyclosporine dose. CYP3A7*1C carriers required a 1.4-fold to 1.6-fold higher cyclosporine daily dose during the first year after transplantation (P < 0.05). In conclusion, CYP3A4, CYP3A5, and CYP3A7 polymorphisms affect cyclosporine metabolism, and therefore, their genotyping could be useful, in association with therapeutic drug monitoring, to prospectively optimize cyclosporine prescription in transplant recipients. The administration of a CYP3A genotype-dependent cyclosporine starting dose should therefore be tested prospectively in a randomized controlled clinical trial to assess whether it leads to an improvement of the patients outcome after transplantation, with adequate immunosuppression and decreased toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978522     DOI: 10.1097/FTD.0b013e31818a2a60

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  27 in total

Review 1.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

2.  Tigecycline and cyclosporine interaction-an interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2009-02-18       Impact factor: 2.953

Review 3.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

4.  Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ho-Ching Chiu; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  World J Hepatol       Date:  2013-11-27

5.  Pharmacokinetic interaction studies of fenugreek with CYP3A substrates cyclosporine and carbamazepine.

Authors:  Fahad I Al-Jenoobi; Mohd Aftab Alam; Khalid M Alkharfy; Saleh A Al-Suwayeh; Hesham M Korashy; Abdullah M Al-Mohizea; Muzaffar Iqbal; Abdul Ahad; Mohammad Raish
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06       Impact factor: 2.441

6.  IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.

Authors:  Mou-Ze Liu; Hai-Yan He; Yue-Li Zhang; Yong-Fang Hu; Fa-Zhong He; Jian-Quan Luo; Zhi-Ying Luo; Xiao-Ping Chen; Zhao-Qian Liu; Hong-Hao Zhou; Ming-Jie Shao; Ying-Zi Ming; Hua-Wen Xin; Wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

7.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

Review 8.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

9.  Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Ioana Stancu; Abdel-Messieh Alnawaqil; Christophe Bula; Serge Zumbach; Michel Gaillard; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

10.  ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.

Authors:  Montserrat García; Rosa María Macías; Juan José Cubero; Julio Benítez; Francisco Caravaca; Guillermo Gervasini
Journal:  Eur J Clin Pharmacol       Date:  2012-08-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.